01—Abstract
Summary
Summary of the 8-K filed October 26, 2026. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (WST) entered into a new Credit Agreement on October 26, 2026 with Bank of America, N.A., as administrative agent, swing line lender and an issuing lender, and the other lenders party thereto.
The new facility includes a revolving credit facility of up to $750 milliona outstanding at any one time and a $200 million term loan advanced on the Effective Date, with a five-year term from that date. Borrowings are unsecured, and as of the Effective Date there are no subsidiary guarantors. Concurrently, the Company used a portion of the proceeds from the New Credit Agreement to prepay the $130.0 million principal outstanding under its Existing Credit Agreement, dated March 28, 2019, and terminated that agreement and related loan documents.
The Company reported no early termination penalties. The New Credit Agreement includes a Net Leverage Ratio covenant, capped at 3.50 to 1.0 (or 4.00 to 1.0 during material acquisition periods, subject to limitations).
Pricing is tied to this ratio, with term SOFR-based revolving margins ranging from 1.000%b to 1.500% and term loan margins from 1.125% to 1.750%. The Company intends to use proceeds for working capital, capital expenditures, general corporate purposes including acquisitions and share repurchases, and debt repayment.
02—Key points
Key Highlights
- New $750 million revolving credit facility, with up to $50 million in letters of credit and $90 million in swing line loans as sublimits.
- $200 million term loan advanced on the Effective Date, with quarterly amortization beginning March 31, 2028 of $1.25 million to $2.5 million per quarter.
- Five-year term from October 26, 2026, with extension mechanics for the revolving facility.
- $130.0 million outstanding under the 2019 Credit Agreement was repaid in full and that agreement was terminated, with no early termination penalties.
- Multicurrency revolver permits borrowings in U.S. dollars, Euros, Yen, Singapore dollars and other approved currencies.
- Unsecured borrowings; covenant caps Net Leverage Ratio at 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods.
- Pricing ranges from 1.000% to 1.500% (revolver SOFR) and 1.125% to 1.750% (term loan SOFR), with commitment fees of 0.125% to 0.225% on unused revolving commitments.
03—Questions
Frequently Asked Questions
What new financing did West Pharmaceutical enter into?
On October 26, 2026, the Company entered into a Credit Agreement providing a $750 million revolving credit facility and a $200 million term loan, with Bank of America, N.A. as administrative agent.
Was the existing debt refinanced?
Yes. The Company used proceeds from the new agreement to prepay the $130.0 million outstanding under its Credit Agreement dated March 28, 2019, and terminated that agreement and its associated loan documents. No early termination penalties were incurred.
When does the term loan begin to amortize?
Quarterly amortization payments of $1.25 million to $2.5 million begin March 31, 2028, with the remaining balance due at maturity.
What financial covenant applies to the new facility?
The Company must keep its Net Leverage Ratio, measured as Net Consolidated Debt to Modified EBITDA over the preceding four fiscal quarters, at no more than 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods, subject to certain limitations.
Are the borrowings secured by company assets or guaranteed by subsidiaries?
No. Borrowings are unsecured, and as of the Effective Date there are no subsidiary guarantors, although certain subsidiaries are required to guarantee obligations under the agreement subject to specified exceptions.
04—Continue